NCT00167947View on ClinicalTrials.gov

Study Evaluating Sirolimus in Kidney Transplant Recipients.

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Kidney FailureGraft vs Host Disease
Interventions
DRUG

Cyclosporine

"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "

DRUG

Steroids

"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "

DRUG

Rapamune (Sirolimus)

"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "

Trial Locations (14)

20162

Milan

21100

Varese

37100

Udine

40138

Bologna

50139

Florence

53100

Siena

56100

Pisa

67100

L’Aquila

70100

Bari

90127

Palermo

00144

Rome

00168

Rome

09125

Cagliari

07100

Sassari

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00167947 - Study Evaluating Sirolimus in Kidney Transplant Recipients. | Biotech Hunter | Biotech Hunter